PortalPublikationenMagnetic resonance imaging and ultrasound for prediction of ...

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

Standard

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. / Graeser, Monika; Schrading, Simone; Gluz, Oleg; Strobel, Kevin; Herzog, Christopher; Umutlu, Lale; Frydrychowicz, Alex; Rjosk-Dendorfer, Dorothea; Würstlein, Rachel; Culemann, Ralph; Eulenburg, Christine; Adams, Jascha; Nitzsche, Henrik; Prange, Anna; Kümmel, Sherko; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Potenberg, Jochem; von Schumann, Raquel; Aktas, Bahriye; Kolberg-Liedtke, Cornelia; Harbeck, Nadia; Kuhl, Christiane K; Nitz, Ulrike.

in: BREAST CANCER RES, Jahrgang 23, Nr. 1, 36, 18.03.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Graeser, M, Schrading, S, Gluz, O, Strobel, K, Herzog, C, Umutlu, L, Frydrychowicz, A, Rjosk-Dendorfer, D, Würstlein, R, Culemann, R, Eulenburg, C, Adams, J, Nitzsche, H, Prange, A, Kümmel, S, Grischke, E-M, Forstbauer, H, Braun, M, Potenberg, J, von Schumann, R, Aktas, B, Kolberg-Liedtke, C, Harbeck, N, Kuhl, CK & Nitz, U 2021, 'Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials', BREAST CANCER RES, Jg. 23, Nr. 1, 36. https://doi.org/10.1186/s13058-021-01413-y

APA

Graeser, M., Schrading, S., Gluz, O., Strobel, K., Herzog, C., Umutlu, L., Frydrychowicz, A., Rjosk-Dendorfer, D., Würstlein, R., Culemann, R., Eulenburg, C., Adams, J., Nitzsche, H., Prange, A., Kümmel, S., Grischke, E-M., Forstbauer, H., Braun, M., Potenberg, J., ... Nitz, U. (2021). Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. BREAST CANCER RES, 23(1), [36]. https://doi.org/10.1186/s13058-021-01413-y

Vancouver

Graeser M, Schrading S, Gluz O, Strobel K, Herzog C, Umutlu L et al. Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. BREAST CANCER RES. 2021 Mär 18;23(1). 36. https://doi.org/10.1186/s13058-021-01413-y

Bibtex

@article{779682c0b8734861ba51a9f4da339d87,
title = "Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials",
abstract = "BACKGROUND: Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes.METHODS: Imaging was performed after 12-week NAT in patients enrolled into three neoadjuvant WSG ADAPT subtrials. Imaging performance was analyzed for prediction of residual tumor measuring ≤10 mm and summarized using positive (PPV) and negative (NPV) predictive values.RESULTS: A total of 248 and 588 patients had MRI and ultrasound, respectively. Tumor size was over- or underestimated by < 10 mm in 4.4% and 21.8% of patients by MRI and in 10.2% and 15.8% by ultrasound. Overall, NPV (proportion of correctly predicted tumor size ≤10 mm) of MRI and ultrasound was 0.92 and 0.83; PPV (correctly predicted tumor size > 10 mm) was 0.52 and 0.61. MRI demonstrated a higher NPV and lower PPV than ultrasound in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive and in HR-/HER2+ tumors. Both methods had a comparable NPV and PPV in HR-/HER2- tumors.CONCLUSIONS: In HR+/HER2+ and HR-/HER2+ breast cancer, MRI is less likely than ultrasound to underestimate while ultrasound is associated with a lower risk to overestimate tumor size. These findings may help to select the most optimal imaging approach for planning surgery after NAT.TRIAL REGISTRATION: Clinicaltrials.gov , NCT01815242 (registered on March 21, 2013), NCT01817452 (registered on March 25, 2013), and NCT01779206 (registered on January 30, 2013).",
keywords = "Adult, Aged, Breast Neoplasms/diagnostic imaging, Female, Humans, Magnetic Resonance Imaging, Middle Aged, Neoadjuvant Therapy, Neoplasm, Residual, Predictive Value of Tests, Receptor, ErbB-2/metabolism, Receptors, Estrogen/metabolism, Receptors, Progesterone/metabolism, Tumor Burden, Ultrasonography, Mammary",
author = "Monika Graeser and Simone Schrading and Oleg Gluz and Kevin Strobel and Christopher Herzog and Lale Umutlu and Alex Frydrychowicz and Dorothea Rjosk-Dendorfer and Rachel W{\"u}rstlein and Ralph Culemann and Christine Eulenburg and Jascha Adams and Henrik Nitzsche and Anna Prange and Sherko K{\"u}mmel and Eva-Maria Grischke and Helmut Forstbauer and Michael Braun and Jochem Potenberg and {von Schumann}, Raquel and Bahriye Aktas and Cornelia Kolberg-Liedtke and Nadia Harbeck and Kuhl, {Christiane K} and Ulrike Nitz",
year = "2021",
month = mar,
day = "18",
doi = "10.1186/s13058-021-01413-y",
language = "English",
volume = "23",
journal = "BREAST CANCER RES",
issn = "1465-5411",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

AU - Graeser, Monika

AU - Schrading, Simone

AU - Gluz, Oleg

AU - Strobel, Kevin

AU - Herzog, Christopher

AU - Umutlu, Lale

AU - Frydrychowicz, Alex

AU - Rjosk-Dendorfer, Dorothea

AU - Würstlein, Rachel

AU - Culemann, Ralph

AU - Eulenburg, Christine

AU - Adams, Jascha

AU - Nitzsche, Henrik

AU - Prange, Anna

AU - Kümmel, Sherko

AU - Grischke, Eva-Maria

AU - Forstbauer, Helmut

AU - Braun, Michael

AU - Potenberg, Jochem

AU - von Schumann, Raquel

AU - Aktas, Bahriye

AU - Kolberg-Liedtke, Cornelia

AU - Harbeck, Nadia

AU - Kuhl, Christiane K

AU - Nitz, Ulrike

PY - 2021/3/18

Y1 - 2021/3/18

N2 - BACKGROUND: Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes.METHODS: Imaging was performed after 12-week NAT in patients enrolled into three neoadjuvant WSG ADAPT subtrials. Imaging performance was analyzed for prediction of residual tumor measuring ≤10 mm and summarized using positive (PPV) and negative (NPV) predictive values.RESULTS: A total of 248 and 588 patients had MRI and ultrasound, respectively. Tumor size was over- or underestimated by < 10 mm in 4.4% and 21.8% of patients by MRI and in 10.2% and 15.8% by ultrasound. Overall, NPV (proportion of correctly predicted tumor size ≤10 mm) of MRI and ultrasound was 0.92 and 0.83; PPV (correctly predicted tumor size > 10 mm) was 0.52 and 0.61. MRI demonstrated a higher NPV and lower PPV than ultrasound in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive and in HR-/HER2+ tumors. Both methods had a comparable NPV and PPV in HR-/HER2- tumors.CONCLUSIONS: In HR+/HER2+ and HR-/HER2+ breast cancer, MRI is less likely than ultrasound to underestimate while ultrasound is associated with a lower risk to overestimate tumor size. These findings may help to select the most optimal imaging approach for planning surgery after NAT.TRIAL REGISTRATION: Clinicaltrials.gov , NCT01815242 (registered on March 21, 2013), NCT01817452 (registered on March 25, 2013), and NCT01779206 (registered on January 30, 2013).

AB - BACKGROUND: Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes.METHODS: Imaging was performed after 12-week NAT in patients enrolled into three neoadjuvant WSG ADAPT subtrials. Imaging performance was analyzed for prediction of residual tumor measuring ≤10 mm and summarized using positive (PPV) and negative (NPV) predictive values.RESULTS: A total of 248 and 588 patients had MRI and ultrasound, respectively. Tumor size was over- or underestimated by < 10 mm in 4.4% and 21.8% of patients by MRI and in 10.2% and 15.8% by ultrasound. Overall, NPV (proportion of correctly predicted tumor size ≤10 mm) of MRI and ultrasound was 0.92 and 0.83; PPV (correctly predicted tumor size > 10 mm) was 0.52 and 0.61. MRI demonstrated a higher NPV and lower PPV than ultrasound in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive and in HR-/HER2+ tumors. Both methods had a comparable NPV and PPV in HR-/HER2- tumors.CONCLUSIONS: In HR+/HER2+ and HR-/HER2+ breast cancer, MRI is less likely than ultrasound to underestimate while ultrasound is associated with a lower risk to overestimate tumor size. These findings may help to select the most optimal imaging approach for planning surgery after NAT.TRIAL REGISTRATION: Clinicaltrials.gov , NCT01815242 (registered on March 21, 2013), NCT01817452 (registered on March 25, 2013), and NCT01779206 (registered on January 30, 2013).

KW - Adult

KW - Aged

KW - Breast Neoplasms/diagnostic imaging

KW - Female

KW - Humans

KW - Magnetic Resonance Imaging

KW - Middle Aged

KW - Neoadjuvant Therapy

KW - Neoplasm, Residual

KW - Predictive Value of Tests

KW - Receptor, ErbB-2/metabolism

KW - Receptors, Estrogen/metabolism

KW - Receptors, Progesterone/metabolism

KW - Tumor Burden

KW - Ultrasonography, Mammary

U2 - 10.1186/s13058-021-01413-y

DO - 10.1186/s13058-021-01413-y

M3 - SCORING: Journal article

C2 - 33736679

VL - 23

JO - BREAST CANCER RES

JF - BREAST CANCER RES

SN - 1465-5411

IS - 1

M1 - 36

ER -